Droxidopa

Catecholamine — CARDIOVASCULAR SYSTEM

Key facts

Droxidopa is an ofp drug in the Catecholamine class catalogued in DrugCentral. It was first approved by the FDA in 2014. DrugCentral lists 2 molecular targets, including CHRM1 and ADRB2|ADRB1|ADRA2A|ADRB3|ADRA2B|ADRA2C|ADRA1D|ADRA1A|ADRA1B. Recorded indications include Orthostatic hypotension and Parkinson's disease.

• Approval status: ofp (first approved 2014 by the FDA).
• Drug class: Catecholamine.
• Molecular targets: CHRM1 and ADRB2|ADRB1|ADRA2A|ADRB3|ADRA2B|ADRA2C|ADRA1D|ADRA1A|ADRA1B (2 listed in DrugCentral).
• Indications: Orthostatic hypotension and Parkinson's disease.
• ATC code: C01CA27 (Adrenergic and dopaminergic agents).
• Molecular formula: C9H11NO5; molecular weight 213.19 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Orthostatic hypotension
• Parkinson's disease

Mechanism & targets

• Established pharmacologic class: Catecholamine

Molecular targets (2)

Target	Gene	Action	Activity
Muscarinic acetylcholine receptor M1	CHRM1	antagonist	Ki 7.10
Adrenergic receptor	ADRB2|ADRB1|ADRA2A|ADRB3|ADRA2B|ADRA2C|ADRA1D|ADRA1A|ADRA1B	agonist	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2014-02-18	FDA	—	LUNDBECK NA LTD	Yes

ATC classification

ATC code	Therapeutic hierarchy
C01CA27	CARDIOVASCULAR SYSTEM › CARDIAC THERAPY › CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES › Adrenergic and dopaminergic agents

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Dizziness	1565.9
Death	1193.5
Blood pressure increased	1091.7
Product dose omission issue	821.1
Blood pressure decreased	776.2
Fall	752.2
Blood pressure fluctuation	648.2
Loss of consciousness	647.7
Supine hypertension	463.1
Hypotension	439.6
Hypertension	367.2
Headache	336.2

Chemical structure

• Molecular formula: C₉H₁₁NO₅
• Molecular weight: 213.19 g/mol
• CAS number: —
• InChIKey: QXWYKJLNLSIPIN-JGVFFNPUSA-N
• PubChem CID: 439260

N[C@@H]([C@H](O)C1=CC(O)=C(O)C=C1)C(O)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Droxidopa used for?

DrugCentral lists the following indications for Droxidopa: Orthostatic hypotension and Parkinson's disease.

How does Droxidopa work?

Its molecular targets in DrugCentral include CHRM1 (antagonist) and ADRB2|ADRB1|ADRA2A|ADRB3|ADRA2B|ADRA2C|ADRA1D|ADRA1A|ADRA1B (agonist).

When was Droxidopa first approved?

Droxidopa was first approved by the FDA in 2014.

What drug class does Droxidopa belong to?

Droxidopa is in the Catecholamine class.

What is the chemical formula of Droxidopa?

Droxidopa has the molecular formula C9H11NO5 and a molecular weight of 213.19 g/mol.

Sources

• DrugCentral drug card 971 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL2103827 — compound record and bioactivity
• PubChem CID 439260 — chemical identifiers
• DrugBank DB00368 — drug record
• FDA UNII J7A92W69L7 — substance identity
• DailyMed: FDA labels for Droxidopa — current prescribing information (label search)
• UniProt P11229 (CHRM1) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.